{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:24:42Z","timestamp":1790022282901,"version":"4.0.1"},"reference-count":29,"publisher":"The Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Objective: Hyperthyroidism is a well-described cause of hyperphosphatemia. We aimed to clarify the physiological role of fibroblast growth factor (FGF)-23 in serum phosphate homeostasis in patients with Graves\u2019 disease during the course of treatment for hyperthyroidism.<\/jats:p>\n               <jats:p>Context: The study group comprised 56 patients (45 for a cross-sectional study and 11 for a longitudinal study) with Graves\u2019 disease. For the cross-sectional study, patients were assigned, on the basis of their serum phosphate level, to a hypophosphatemia group (n = 14), a normophosphatemia group (n = 16), or a hyperphosphatemia group (n = 15). Serum FGF-23, calcium, phosphate, PTH, and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels were compared between the three groups. For the longitudinal study, we assessed changes in these biochemical indices before and after antithyroid treatment.<\/jats:p>\n               <jats:p>Results: In the cross-sectional study, the serum FGF-23 level was significantly higher (P &amp;lt; 0.05) in the hyperphosphatemia group than in the other groups (61 \u00b1 36 ng\/liter vs. 31 \u00b1 22 ng\/liter and 30 \u00b1 9 ng\/liter). In the longitudinal study, serum levels of FGF-23 decreased significantly (P &amp;lt; 0.05) from a high of 54 \u00b1 12 ng\/liter before treatment to 29 \u00b1 14 ng\/liter after treatment. In contrast, the serum 1,25(OH)2D level increased significantly (P &amp;lt; 0.005) from 55 \u00b1 22 pmol\/liter before treatment to 185 \u00b1 76 pmol\/liter 3 months after treatment. Serum FGF-23 levels were positively correlated with serum phosphate levels (P &amp;lt; 0.0001) and negatively correlated with serum 1,25(OH)2D levels (P &amp;lt; 0.0001).<\/jats:p>\n               <jats:p>Conclusions: The significant positive correlation between serum levels of phosphate and FGF-23 indicates that FGF-23 may play an important role in serum phosphate homeostasis by its up-regulation in the hyperphosphatemic condition.<\/jats:p>","DOI":"10.1210\/jc.2004-2498","type":"journal-article","created":{"date-parts":[[2005,7,7]],"date-time":"2005-07-07T06:50:02Z","timestamp":1120719002000},"page":"4211-4215","source":"Crossref","is-referenced-by-count":28,"title":["Fibroblast Growth Factor-23 in Patients with Graves\u2019 Disease before and after Antithyroid Therapy: Its Important Role in Serum Phosphate Regulation"],"prefix":"10.1210","volume":"90","author":[{"given":"Hiroyuki","family":"Yamashita","sequence":"first","affiliation":[{"name":"Noguchi Thyroid Clinic and Hospital Foundation (H.Y., S.N.), Oita 874-0932, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Labs (Y.Y., H.H., T.Y.), KIRIN Brewery Co. Ltd., Takasaki 370-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Labs (Y.Y., H.H., T.Y.), KIRIN Brewery Co. Ltd., Takasaki 370-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyoshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Labs (Y.Y., H.H., T.Y.), KIRIN Brewery Co. Ltd., Takasaki 370-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology (S.F.), Department of Internal Medicine, Tokyo University Hospital, Tokyo 113-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Division of Nephrology (T.S.), Tokyo-Jikeikai Medical School Aoto Hospital, Katsushika 125-8506, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro James","family":"Kazama","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology (J.J.K.), Niigata University Graduate School of Medicine and Dental Research, Niigata 951-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis Center (M.F.), Kobe University School of Medicine, Kobe 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Noguchi Thyroid Clinic and Hospital Foundation (H.Y., S.N.), Oita 874-0932, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616263675800_R1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1210\/jcem.86.2.7302","article-title":"Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem.","volume":"86","author":"Quarles","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616263675800_R2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1359\/jbmr.2003.18.7.1227","article-title":"Serum FGF23 levels in normal and disordered phosphorus homeostasis.","volume":"18","author":"Weber","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071616263675800_R3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/81664","article-title":"Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.","volume":"26","year":"2000","journal-title":"Nat Genet"},{"key":"2020071616263675800_R4","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJM199406093302304","article-title":"Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia.","volume":"330","author":"Cai","year":"1994","journal-title":"N Engl J Med"},{"key":"2020071616263675800_R5","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","article-title":"Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.","volume":"98","author":"Shimada","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071616263675800_R6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00041552-200207000-00003","article-title":"Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.","volume":"11","author":"Fukumoto","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2020071616263675800_R7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/eje.0.1480269","article-title":"Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia.","volume":"148","author":"Larsson","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"2020071616263675800_R8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.bbrc.2003.12.102","article-title":"FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.","volume":"314","author":"Shimada","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071616263675800_R9","doi-asserted-by":"crossref","first-page":"782","DOI":"10.5694\/j.1326-5377.1974.tb71172.x","article-title":"Hypercalcaemia and thyrotoxicosis.","volume":"2","author":"Farnsworth","year":"1974","journal-title":"Med J Aust"},{"key":"2020071616263675800_R10","first-page":"161","article-title":"Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy.","volume":"6","author":"Langdahl","year":"1996","journal-title":"Thyroid"},{"key":"2020071616263675800_R11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/acta.0.0870751","article-title":"Effect of antithyroid treatment on calcium-phosphorus metabolism in hyperthyroidism. II. Bone histomorphometry.","volume":"87","author":"Mosekilde","year":"1978","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071616263675800_R12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/acta.0.0850515","article-title":"Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism.","volume":"85","author":"Mosekilde","year":"1977","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2020071616263675800_R13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/000456327801500176","article-title":"Plasma 25-hydroxyvitamin D and alkaline phosphatase isoenzymes in hyperthyroidism.","volume":"15","author":"Cleeve","year":"1978","journal-title":"Ann Clin Biochem"},{"key":"2020071616263675800_R14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4158\/EP.9.6.517","article-title":"Hypercalcemia in hyperthyroidism: patterns of serum calcium, parathyroid hormone, and 1,25-dihydroxyvitamin D3 levels during management of thyrotoxicosis.","volume":"9","author":"Iqbal","year":"2003","journal-title":"Endocr Pract"},{"key":"2020071616263675800_R15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1620\/tjem.203.183","article-title":"Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy.","volume":"203","author":"Barsal","year":"2004","journal-title":"Tohoku J Exp Med"},{"key":"2020071616263675800_R16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1210\/jcem-58-1-91","article-title":"A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies.","volume":"58","author":"Reinhardt","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616263675800_R17","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia.","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616263675800_R18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1530\/eje.0.1510055","article-title":"Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism.","volume":"151","author":"Yamashita","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2020071616263675800_R19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI108497","article-title":"Direct stimulation of bone resorption by thyroid hormones.","volume":"58","author":"Mundy","year":"1976","journal-title":"J Clin Invest"},{"key":"2020071616263675800_R20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF00410200","article-title":"Thyroid hormone stimulation of Na\/Pi-cotransport in opossum kidney cells.","volume":"431","author":"Sorribas","year":"1995","journal-title":"Pflugers Arch"},{"key":"2020071616263675800_R21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0026-0495(75)90130-4","article-title":"Comparative response to parathyroid hormone in hyperthyroidism and hypothyroidism.","volume":"24","author":"Castro","year":"1975","journal-title":"Metabolism"},{"key":"2020071616263675800_R22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0026-0495(82)90123-8","article-title":"Serum levels of vitamin D metabolites and bone remodelling in hyperthyroidism.","volume":"31","author":"Jastrup","year":"1982","journal-title":"Metabolism"},{"key":"2020071616263675800_R23","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.2004-0724","article-title":"FGF-23 is elevated by chronic hyperphosphatemia.","volume":"89","author":"Gupta","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616263675800_R24","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"2020071616263675800_R25","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1523-1755.2004.00604.x","article-title":"FGF-23 in patients with end-stage renal disease on hemodialysis.","volume":"65","author":"Imanishi","year":"2004","journal-title":"Kidney Int"},{"key":"2020071616263675800_R26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","article-title":"Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.","volume":"44","author":"Shigematsu","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2020071616263675800_R27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0272-6386(04)00817-0","article-title":"Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.","volume":"44","author":"Sato","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"2020071616263675800_R28","doi-asserted-by":"crossref","first-page":"28265","DOI":"10.1074\/jbc.M202527200","article-title":"Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway.","volume":"277","author":"Yamashita","year":"2002","journal-title":"J Biol Chem"},{"key":"2020071616263675800_R29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1152\/physrev.2000.80.4.1373","article-title":"Proximal tubular phosphate reabsorption: molecular mechanisms.","volume":"80","author":"Murer","year":"2000","journal-title":"Physiol Rev"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/90\/7\/4211\/10776304\/jcem4211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/90\/7\/4211\/10776304\/jcem4211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:16:08Z","timestamp":1594955768000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/90\/7\/4211\/2837412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2004-2498","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}